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Abstract
Introduction Common variants that alter breast cancer risk are
being discovered. Here, we determine how these variants
influence breast cancer prognosis, risk and tumour
characteristics.
Methods We selected 1,001 women with early onset
nonfamilial invasive breast cancer from the Prospective study of
Outcomes in Sporadic versus Hereditary breast cancer (POSH)
cohort and genotyped 206 single nucleotide polymorphisms
(SNPs) across 30 candidate genes. After quality control, 899
cases and 133 SNPs remained. Survival analyses were used to
identify SNPs associated with prognosis and determine their
interdependency with recognized prognostic factors. To identify
SNPs that alter breast cancer risk, association tests were used
to compare cases with controls from the Wellcome Trust Case
Control Consortium. To search for SNPs affecting tumour
biology, cases were stratified into subgroups according to
oestrogen receptor (ER) status and grade and tested for
association.
Results We confirmed previous associations between
increased breast cancer risk and SNPs in CASP8,  TOX3
(previously known as TNRC9) and ESR1. Analysis of prognosis
identified eight SNPs in six genes (MAP3K1, DAPK1, LSP1,
MMP7, TOX3 and ESR1) and one region without genes on
8q24 that are associated with survival. For MMP7, TOX3 and
MAP3K1 the effects on survival are independent of the main
recognized clinical prognostic factors. The SNP in 8q24 is more
weakly associated with independent effects on survival. Once
grade and pathological nodal status (pN stage) were taken into
account, SNPs in ESR1 and LSP1 showed no independent
survival difference, whereas the effects of the DAPK1 SNP were
removed when correcting for ER status. Interestingly, effects on
survival for SNPs in ESR1 were most significant when only ER-
positive tumours were examined. Stratifying POSH cases by
tumour characteristics identified SNPs in FGFR2  and TOX3
associated with ER-positive disease and SNPs in ATM
associated with ER-negative disease.
Conclusions We have demonstrated that several SNPs are
associated with survival. In some cases this appears to be due
to an effect on tumour characteristics known to have a bearing
on prognosis; in other cases the effect appears to be
independent of these prognostic factors. These findings require
validatation by further studies in similar patient groups.
Introduction
Breast cancer arises as a result of multiple somatic molecular
events that can be genetic or epigenetic. Further research is
required to define the inherited factors that contribute to
breast cancer risk. To date, six genes associated with high risk
(BRCA1,  BRCA2,  TP53,  PTEN,  STK11  and  CDH1), four
associated with modest risk (PALB2,  BRIP1,  ATM  and
CHEK2) and six lower penetrance alleles (CASP8, FGFR2,
TOX3, MAP3K1, LSP1 and 8q24 rs13281615) have been
identified using various approaches [1-5]. Genetic variability
CI: confidence interval; DDFS: distant disease-free survival; ER: oestrogen receptor; pN: pathological nodal; HR: hazard ratio; POSH: Prospective 
study of Outcomes in Sporadic versus Hereditary breast cancer; SNP: single nucleotide polymorphism; WTCCC: Wellcome Trust Case Control Con-
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appears to influence not only risk but also the type of breast
cancer that develops in an individual. There is compelling data
that pathogenic mutations in BRCA1  result in a distinct
tumour phenotype, whereas more subtle similarities are seen
between  BRCA2  cases and among familial non-BRCA1/
BRCA2 cancers [6-9]. In studies of lower penetrance alleles
it is clear that most of the increase in breast cancer risk is for
oestrogen receptor (ER)-positive breast cancers (which form
the majority of most breast cancer cohorts) [10-12]. There is
some evidence that breast cancer prognosis may be influ-
enced by inherited genetic factors. Ethnicity appears to be
associated with tumour biology and outcome [13,14]. Recent
data from a large Swedish population-based study indicated
that the prognosis of mothers with breast cancer influenced
the likelihood of survival in their daughters who subsequently
developed breast cancer, suggesting an inherited component
to prognosis [15]. It is also apparent that inherited genetic fac-
tors can influence drug metabolism, and this may affect prog-
nosis after breast cancer diagnosis by influencing the efficacy
of treatment [16,17].
As an example of this it is apparent that ER-modulating drugs
reduce the risk for developing ER-positive breast cancer by up
to 50%, but they do not alter the incidence of ER-negative
breast cancer [18]. If a given genetic risk profile indicates a
raised likelihood of developing ER-positive breast cancer spe-
cifically, then targeting this group of individuals with tamoxifen
or raloxifene treatment as a prevention strategy would give the
most benefit.
Early onset breast cancers are more likely to have arisen due
to an inherited predisposition and tend to have a worse prog-
nosis, possibly as a result of a different pattern of genomic
expression compared with tumours developing in older
women [19]. Women with early onset breast cancer are thus
an ideal population in which to search for common genetic var-
iants that may influence breast cancer risk and prognosis. The
discovery of such genetic markers may allow clinicians to
advise patients more accurately about appropriate prevention
and screening strategies, tumour prognosis and treatment.
Materials and methods
Patient cohort
To identify SNPs associated with prognosis, risk and tumour
characteristics, we selected 1,001 women from the Prospec-
tive study of Outcomes in Sporadic versus Hereditary breast
cancer (POSH) cohort for genotyping of 30 genes with prior
evidence for biological relevance [see Additional data file 1].
Full details of the POSH study can be obtained from the pub-
lished protocol [20]. The subset of 1,001 POSH patients are
all incident cases who were aged 40 years or younger at diag-
nosis of invasive carcinoma between January 2000 and
December 2007 and have no family history of breast cancer or
ovarian cancer (all recruits had submitted family history details,
collected by questionnaire). These cases are therefore least
likely to carry a high risk susceptibility allele such as BRCA1
or  BRCA2. To date, comprehensive BRCA1  and  BRCA2
mutation screening (using a combination of conformation sen-
sitive capillary electrophoresis and multiplex ligation-depend-
ent probe amplification) has been carried out in 120 patients
from the POSH cohort, 39 of which reported no family history
of breast or ovarian cancer. For those without family history,
one in 39 (2.5%) had a pathogenic BRCA1 mutation and no
pathogenic BRCA2 mutations were found (unpublished data).
This subset of POSH cases all presented symptomatically,
which means the tumour biology and clinical features have not
been modified by earlier detection in a screening programme.
The effect of tumour biology on prognosis is reflected in the
known clinical prognostic factors (tumour size and grade, ER
status and pathological nodal [pN] status). These parameters
are used to make decisions about adjuvant therapy [21] and
have been recorded for all POSH cases. On the basis of these
factors, the subset of POSH cases were stratified into sub-
groups and compared to identify common variants that affect
tumour biology.
Genotyping and quality control
A total of 206 tag single nucleotide polymorphisms (SNPs)
across 30 genes were selected for genotyping, ensuring cov-
erage of each gene and its promoter region with r2 ≥ 0.9 (r2
between adjacent SNPs in candidate genes) using data from
the HapMap project [22]. Genotyping was carried out by
Sequenom (San Diego, CA, USA) using the iPLEX service,
which is based on mass spectrometry. A little more than one-
third of these SNPs (35%, 73) were removed by a screening
procedure that rejected SNPs with ≥10% missing genotypes
(60) or allele frequencies less than 5% (12). Typically, devia-
tions from Hardy-Weinberg equilibrium in controls would be
used to exclude SNPs. However, because only cases were
genotyped, Hardy-Weinberg deviations may reflect associa-
tion with breast cancer, rather than poor genotyping. We
therefore verified genotyping calls by examining the Seque-
nom cluster plots for SNPs with significant deviations from
Hardy-Weinberg equilibrium (χ2 ≥ 10). On this basis, one SNP
was removed leaving 133 (64%) for analysis, which is consist-
ent with the genotyping tier [see Additional data file 1]. A high
proportion of missing genotypes per individual DNA sample
may suggest relatively poor DNA quality. Most samples had
very low rates of missing data, and we removed 58 individuals
with ≥ 10% missing genotypes, leaving 943 for further analy-
sis.
Because population stratification may cause false positives in
association studies, and the majority of individuals in the
POSH cohort have Western European ancestries, we
removed individuals with apparently different ancestries. We
used the PLINK program [23] to perform multidimensional
scaling on genome-wide average identities by state. To avoid
confounding of the multidimensional scaling by including anyAvailable online http://breast-cancer-research.com/content/10/6/R108
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nonindependent SNPs due to extended linkage disequilibrium,
we thinned the data to 82 autosomal SNPs with maximum
pair-wise r2 ≤ 0.2. These data were merged with data from the
founders or unrelated individuals in the HapMap sample [22]:
60 Western European (CEU), 60 Nigerian (YRI), 45 Han Chi-
nese (CHB) and 45 Japanese (JPT). Before merging the gen-
otypic data from POSH and HapMap, we ensured that all
genotypes were configured to the positive strand of the refer-
ence sequence (National Cancer for Biotechnology Informa-
tion [NCBI] build 36.1). Although more than 10,000
autosomal SNPs are recommended for this type of analysis
[23], plotting the first two components from the multidimen-
sional scaling analysis of 82 SNPs, which represent geo-
graphic and genetic variation, clearly identifies three distinct
clusters that correspond to African, Asian, and Western Euro-
pean ancestries (Figure 1). Given this, we were able to
exclude 44 samples (35 African and 9 Asian) that did not align
with the Western European cluster, leaving 899 for analysis.
The genotyping call rate for the 133 SNPs and 899 individuals
passing our quality control procedure is 99%.
Statistical analysis
To identify SNPs influencing prognosis and because the
median follow-up time for the 899 patients passing quality
control is only 2.4 years (Table 1), we calculated distant dis-
ease-free survival (DDFS) times that we define as the time
between diagnosis and the first distant metastasis. This is a
surrogate for overall survival because the majority of patients
with distant metastases will not survive the disease. In seven
cases, the date of death was used because the date of distant
metastasis was not available. In one of these cases the cause
of death was known to be unrelated to breast cancer. Univari-
ate analyses of DDFS were performed using the log rank test
to compare Kaplan-Meier DDFS curves for the three geno-
types of each SNP.
Data on ER status (positive/negative), histological grade (1 to
3), invasive tumour diameter (not including ductal carcinom in
situ component 0.5 to 180 mm), and axillary nodal status (1/
0) were available for 828 (92.1%) of the cases passing the
quality control procedure. We were therefore able to deter-
mine whether SNPs with significant impacts on survival were
independent of the known prognostic factors by treating them
as covariates in Cox's proportional hazards model. For each
SNP genotype, hazard ratios (HRs) and 95% confidence inter-
vals (CIs) were determined using the common allele homozy-
gotes as the reference group. For SNPs with 10 or fewer
minor allele homozygotes, the minor allele homozygotes were
combined with heterozygotes. Dominant and recessive dis-
ease models were also tested, and the assumption of propor-
tional hazards was tested using log-log plots.
To search for SNPs affecting tumour biology, we stratified the
899 cases into major subgroups on the basis of ER status
(positive or negative) and grade (1 or 3). Because tumour
grade is necessarily a subjective classification and some
grade 2 tumours have gene expression signatures similar to
those of grade 1 or grade 3 tumours [24], many grade 2
tumours might be reclassified as either grade 1 or 3. We there-
fore elected to compare the extremes of grade 1 versus grade
3. The 133 SNPs were individually tested for association using
Cochran-Armitage trend test and two-by-three tables of dis-
ease-by-genotype.
Although our study was not designed primarily to detect SNPs
that increase breast cancer risk, we explored risk associations
by contrasting POSH cases with genotyping data in controls
that were obtained from the Wellcome Trust Case Control
Consortium (WTCCC) [25]. Multidimensional scaling analysis
of the WTCCC and HapMap data involving 60,364 SNPs was
used to infer Western European ancestry for 2,980 of the
3,000 WTCCC controls from the National Blood Service and
the 1958 British Birth Cohorts. The 28 SNPs that were typed
in both POSH and WTCCC datasets [see Additional data file
1] were individually tested for association using Cochran-
Armitage trend test and two-by-three tables of disease-by-
genotype to contrast POSH cases with WTCCC controls.
To determine accurate levels of significance, it is important to
correct for the number of tests performed. However, the most
effective approach to correct for multiple tests has yet to be
defined. The HapMap Consortium has proposed that adjust-
ments should be made for the total number of independent
tests. For tests of prognosis and tumour biology, 133 SNPs
were used, and 82 of these in 30 genes were determined to
be independent by the multidimensional scaling procedure
with maximum pair-wise r2 values of less than 0.2. For these
Figure 1
Inference of ancestry by multidimensional scaling Inference of ancestry by multidimensional scaling. POSH and Hap-
Map samples plotted for the first two principal components obtained by 
multidimensional scaling of a matrix of pairwise identity by state values. 
Excluded POSH samples, filled black circles, occur near the YRI and 
CHB+JPT clusters. CHB, Chinese; CUE, Western European; JPT, Jap-
anese; POSH, Prospective study of Outcomes in Sporadic versus 
Hereditary breast cancer; YRI, Nigerian.Breast Cancer Research    Vol 10 No 6    Tapper et al.
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tests, the threshold for significance is a P value of 0.0006
(0.05/82). Only 28 SNPs in 17 genes were tested when
searching for SNPs associated with risk for breast cancer. A
conservative Bonferroni correction requires P values less than
0.003 (0.05/17) to be considered significant for these tests.
We used SPSS 14.0 (SPSS Inc., San Francisco, CA, USA) to
perform Kaplan Meier and Cox regressions and PLINK [23] to
carry out Cochran-Armitage trend tests and genotypic tests.
Ethics approval for this research was granted by the South
West Multi-Centre Research Ethics Committee (MREC/00/6/
69). All patients recruited to POSH gave fully informed written
consent.
Results
Phenotypic characteristics of the POSH cohort
The phenotypic characteristics of this subset of the POSH
cohort are based on clinical and pathological assessment per-
formed at the time of diagnosis. The distribution of grade and
ER status in 873 cases that passed quality control and have
this phenotypic information available are shown in Table 1.
Compared with women aged 40 years and older at diagnosis,
the subset of POSH study women have nearly 10% more ER-
negative tumours (30.9% in POSH versus 21.4% in women
aged ≥ 40 years) [26].
Association of SNPs with breast cancer risk (cases 
versus controls)
Testing the 28 SNPs that were also typed in the WTCCC con-
firmed previous associations between risk for breast cancer
and the same SNPs in TOX3 and ESR1 [3,5,27] (Table 2).
Table 1
Distribution of prognostic phenotypes in 899 patients from the POSH cohort according to outcome
Outcome Number DDFSa ER statusb Tumour gradeb Diameter 
(cM)
pN stageb
Negative Positive 1 2 3 1 0
Deceased 102 1.48 
(0.00 to 
4.77)
53 (53.0) 47 (47.0) 2 (2.0) 19 (19.2) 78 (78.8) 3.67 70 (76.9) 21 (23.1)
Distant 
relapse
55 1.90 
(0.00 to 
4.62)
18 (32.7) 37 (67.3) 2 (3.8) 18 (34.0) 33 (62.0) 3.00 38 (74.5) 13 (25.5)
Disease free 742 2.61 
(0.05 to 
6.69)
202 (27.6) 531 (72.4) 60 (8.2) 269 (36.8) 402 (55.0) 2.58 352 (48.4) 376 (51.6)
Total 899 2.44 
(0.00 to 
6.69)
273 (30.7) 615 (69.3) 64 (7.2) 306 (34.7) 513 (58.1) 2.72 460 (52.9) 410 (47.1)
aDistant disease free survival times in years and (range). bNumbers outside parenthesis represent counts while those inside are percentages of 
the total number in each outcome group. DDFS, distant disease-free survival; ER, ostrogen receptor; pN, pathological nodal; POSH, Prospective 
study of Outcomes in Sporadic versus Hereditary breast cancer.
Table 2
Risk of breast cancer comparing 899 POSH cases with 2,980 WTCCC controls
Gene SNP Risk allele Frequency Trend test Genotypic test P value
Cases Controls OR (95% CI) P value
TOX3 rs3803662 A 0.2905 0.2567 1.19 (1.05 to 1.33) 0.0054 0.0188
CASP8 rs12693932 T 0.4933 0.4552 1.17 (1.05 to 1.30) 0.0051 0.0144
ESR1 rs2228480 A 0.2007 0.2308 0.84 (0.73 to 0.95) 0.0064 0.0053
ADH1B rs1042026 C 0.3068 0.2803 1.13 (1.01 to 1.28) 0.0307 0.0975
ESR1 rs3798577 C 0.4983 0.4713 1.11 (1.00 to 1.24) 0.0441 0.1231
CI, confidence interval; OR, odds ratio; POSH, Prospective study of Outcomes in Sporadic versus Hereditary breast cancer; SNP, single 
nucleotide polymorphism; WTCCC, Wellcome Trust Case Control Consortium.Available online http://breast-cancer-research.com/content/10/6/R108
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We also identified an association with rs12693932 in the
CASP8 gene that has previously been implicated [1]. How-
ever, we report an increased risk with rs12693932, whereas
the previous study found a protective effect with rs1045485,
which failed to pass our quality control procedure. Unfortu-
nately, none of these SNPs remain significant after conserva-
tive correction for multiple tests. The SNPs in FGFR2 from our
study were not typed as part of the WTCCC, and so these
could not be included in this analysis.
SNPs affecting prognosis
To determine whether any of the SNPs affect the duration of
DDFS, Kaplan Meier DDFS analysis was conducted in the
133 SNPs that passed the quality control procedure. Before
conservative correction for multiple tests, seven of these
SNPs, representing six genes, were found to have significant
associations with DDFS (Figure 2). Carriers of the minor alle-
les for five of these SNPs had poorer DDFS, and there was
improved DDFS for carriers of two of the SNPs. Data on ER
status, histological grade, tumour diameter, and pN stage
were available for 828 (92.1%) of the cases passing the qual-
ity control procedure. We therefore used Cox regression anal-
ysis to determine whether SNPs associated with DDFS were
independent of these known prognostic factors by treating
them as covariates in the hazard models. After adjustment for
ER status, histological grade, tumour diameter and pN stage,
three of the seven SNPs identified by the Kaplan Meier analy-
sis remained significant. One additional SNP in TOX3 was
found to be associated with DDFS by Cox regression (Table
3) but did not reach significance in the Kaplan-Meier analysis.
However, these SNPs do not remain significant after conserv-
ative correction for the 82 independent tests.
We found a protective effect against the development of dis-
tant metastases among cases with the rare C allele of
rs1943779 in the MMP7 (matrix metalloproteinase 7) gene
(rare allele homozygotes HR = 0.217, 95% CI = 0.069 to
0.689; heterozygote HR = 0.702, 95% CI = 0.490 to 1.005)
and significant heterogeneity among genotypes (P = 0.009).
For the TOX3 gene, which has been shown to be associated
with an increased risk for breast cancer in published case con-
trol studies, the rare allele homozygotes of rs1420542 (TT; n
= 41) and heterozygotes (TA; n = 223) showed a 2.1-fold and
1.6-fold risk for distant metastases, respectively, compared
with common allele homozygotes. Heterogeneity among gen-
otypes was significant (P  = 0.013), but this SNP did not
achieve statistical significance in the Kaplan-Meier analysis (P
= 0.077).
The SNP rs889312 in MAP3K1 (which encodes MEK kinase)
showed a significant improvement in DDFS for heterozygotes
Table 3
Summary of most significant SNPs associated with survival independent of known prognostic factors using Cox proportional 
hazards analysis
Gene/SNP Genotype n Events Censored Median survival (years) Hazard ratio 95% CI P value
MAP3K1/rs889312 AA 383 76 307 2.393 Reference
CA 361 48 313 2.577 0.624 0.435 to 0.897 0.011
CC 82 10 72 2.508 0.627 0.324 to 1.215 0.166
Dominant 443 58 385 2.564 0.625 0.443 to 0.881 0.007
Desert/rs13281615 AA 280 51 229 2.531 Reference
GA 375 49 326 2.517 0.749 0.504 to 1.113 0.153
GG 170 34 136 2.326 1.349 0.871 to 2.089 0.180
Recessive 170 34 136 2.326 1.569 1.060 to 2.323 0.024
MMP7/rs1943779 TT 429 85 344 2.431 Reference
CT 331 47 283 2.477 0.702 0.490 to 1.005 0.053
CC 67 3 54 2.847 0.217 0.069 to 0.689 0.009
Dominant 398 50 337 2.539 0.617 0.435 to 0.876 0.007
TOX3/rs1420542 AA 551 80 471 2.523 Reference
TA 223 47 176 2.487 1.601 1.114 to 2.300 0.011
TT 41 8 33 1.970 2.069 0.995 to 4.303 0.052
Dominant 264 55 209 2.407 1.654 1.170 to 2.339 0.004
CI, confidence interval; SNP, single nucleotide polymorphism.Breast Cancer Research    Vol 10 No 6    Tapper et al.
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of this SNP (HR = 0.624, 95% CI = 0.435 to 0.897) and
appears to demonstrate a dominant effect, but DDFS in rare
homozygotes (HR = 0.627, 95% CI 0.324 to 1.215) was not
significant, despite significant heterogeneity between geno-
types (P = 0.027).
For rs13281615 at chromosome location 8q24 (no known
genes), the evidence for effects that are independent of the
known prognostic factors is much weaker because significant
results were only obtained for the recessive disease model
(HR = 1.569, 95% CI = 1.060 to 2.323).
For the four remaining SNPs that did not show significant
associations after correcting for ER, grade, tumour size and
pN stage, further Cox regressions were performed that treated
these factors separately to determine which of them are corre-
lated with the SNP's effect on DDFS. The survival effects of
SNPs in ESR1  and LSP1  were no longer significant after
grade and pN stage were accounted for, whereas the survival
effect associated with the DAPK1 SNP was attributable to ER
status, using Cox regression analysis.
Association of genotype with tumour phenotype
To confirm the relationships between SNP genotypes and
prognostic tumour phenotypes and to search for additional
SNPs, we stratified the 899 cases into major subgroups on
the basis of ER status (positive or negative) and grade (1 or 3)
and tested the 133 SNPs for association using Cochran-
Armitage trend test and genotypic tests. Nine SNPs have
nominally significant associations, five with ER status and four
Figure 2
SNPs affecting prognosis identified by Kaplan-Meier analysis SNPs affecting prognosis identified by Kaplan-Meier analysis. Survival curves for rare homozygotes are shown as black lines. The dark grey lines 
represent survival curves for heterozygotes, and the light grey broken lines depict survival curves for common homozygotes. c2 and associated P val-
ues are derived from the log-rank test.Available online http://breast-cancer-research.com/content/10/6/R108
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with grade (Table 4). Of these, three remain significant after
Bonferroni correction for the 82 independent SNPs tested
(rs2981582 and rs1219648 in FGFR2, and rs1801516 in
ATM, with P < 0.0006) and four were in genes shown to have
significant effects on the risk for developing distant metastasis
(rs1420546 in TOX3, rs2228480 and rs3798577 in ESR1,
and rs661348 in LSP1). Comparison of genotypes in patients
developing ER-negative tumours with those developing ER-
positive tumours demonstrated that SNPs in FGFR2  and
TOX3  are associated with the development of ER-positive
breast cancers. In contrast, SNPs in ATM were strongly asso-
ciated with ER-negative breast cancer (Table 4). Comparison
of genotypic extremes of grade (grade 1 versus grade 3) dem-
onstrated a significant difference in genotype frequencies for
ESR1, IGF1 and LSP1 (Table 4).
Discussion
This study utilizes a large group of breast cancer cases
derived from the POSH study cohort [20] to identify common
variants associated with clinical prognostic tumour character-
istics and duration of DDFS. The early age of onset, minimal
number of cases carrying high risk genes, and preservation of
the natural history of tumours offer a unique opportunity to
study young onset breast cancer. Our results from this young
onset group of patients are in line with several previous signif-
icant findings. For example, SNPs in TOX3 and CASP8 alter
the risk for developing breast cancer, and SNPs in FGFR2 and
TOX3 are strongly associated with ER-positive breast cancer
[1,3,10]. These observations remain significant after stringent
correction for multiple tests (Table 4) and reinforce the impor-
tance of distinguishing between subtypes of breast cancer.
Novel findings presented in this pilot study include the obser-
vation that SNP rs1943779 in the MMP7 gene is associated
with improved DDFS after breast cancer diagnosis. Two adja-
cent SNPs in the ERα gene affect tumour grade and DDFS.
Although these results are significant, they fail to pass correc-
tion for multiple testing and require replication in larger stud-
ies.
Our observations in the ESR1 gene are interesting and may
have therapeutic implications. ESR1 encodes the ERα, and its
expression in tumour cells is a prognostic and predictive factor
that is routinely used when making decisions on hormonal
therapy. ER-negative tumours have poorer prognosis when
compared with ER-positive ones. This is largely due to the
higher rate of recurrence in the first 5 years after diagnosis
[28]. ER-negative tumours do not respond to oestrogen mod-
ulating therapies. Many, although not all, ER-positive tumours
respond to medical and surgical approaches that reduce or
block the effects of endogenous oestrogen. We observed two
SNPs in the 3' region of ESR1 that are associated with breast
cancer risk, namely rs2228480 and rs3798577. The strength
of linkage disequilibrium between these SNPs is low (r2 = 0.2),
despite them being separated by just over 1 kilobase. The G
allele of rs2228480 and the C allele of a different SNP,
rs3020410 in the 5' region of ESR1, are associated with an
increased risk for relapse. Although there was no association
of these SNPs with tumour ER status, the difference in survival
between genotypes was most significant when examining only
patients with ER-positive tumours (for rs2228480, survival
analysis for the ER-positive tumours only gave χ2 = 9.12 [P =
0.01] and that for the ER-negative tumours yielded χ2 = 0.5 [P
= 0.78]).
Data on treatment with anti-oestrogenic therapies were availa-
ble for 99% of the patients genotyped in this study. For those
with ER-positive tumours, 93% received adjuvant therapy with
Table 4
Comparison of extremes of phenotypic subgroups
Phenotype Gene SNP Risk allele Frequency Trend test Genotypic P value
ER positive ER negative P value OR (95% CI)
ER (+/-) FGFR2 rs2981582 A 0.478 0.3608 0.000003* 1.62 (1.32 to 2.00) 0.000014
FGFR2 rs1219648 G 0.4861 0.3736 0.000008* 1.59 (1.29 to 1.95) 0.000039
ATM rs1801516 A 0.1085 0.1776 0.000273* 0.56 (0.42 to 0.75) 0.000402
TOX3 rs1420546 C 0.3655 0.2865 0.002135 1.44 (1.15 to 1.79) 0.003002
ATM rs3092991 G 0.1248 0.1813 0.002561 0.64 (0.49 to 0.85) 0.00212
Grade (1/3) ESR1 rs2228480 A 0.2178 0.1032 0.002962 2.42 (1.34 to 4.38) NA
ESR1 rs3798577 C 0.5088 0.373 0.004411 1.74 (1.19 to 2.55) 0.002136
IGF1 rs2373721 G 0.25 0.1406 0.007009 2.04 (1.21 to 3.42) NA
LSP1 rs661348 C 0.3694 0.4921 0.009682 0.60 (0.42 to 0.88) 0.01541
The genotypic test is not performed if at least one of the cells has a frequency less than 5 which is represented by NA. *Significant SNPs after 
correcting for 82 independent tests. CI, confidence interval; ER, oestrogen receptor; OR, odds ratio; SNP, single nuceotide polymorphism.Breast Cancer Research    Vol 10 No 6    Tapper et al.
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anti-oestrogenic modalities, mainly tamoxifen. There are two
possible mechanisms through which this survival effect may
be mediated. Because there is an association with increased
grade, the effect may be through influencing the rate of prolif-
eration of tumours in response to endogenous oestrogen (all
patients were premenopausal). Alternatively, the outcome may
reflect an effect of this SNP on responsiveness to anti-oestro-
gen therapies – particularly tamoxifen. Whatever the function-
ally relevant variant in this region, it is unlikely to be any of the
three alleles typed in this study because rs2228480 is a syn-
onymous variant (no change in amino acid coded), rs3798577
is in the 3' untranslated region of the gene, and rs3020410 is
intronic.
We also identified four SNPs that may be novel predictors of
outcome that are independent of known clinical prognostic
factors. The rs1943779 SNP is in the promoter region of
MMP7 and was found to be associated with improved survival.
Proteins of the matrix metalloproteinase family are involved in
the breakdown of extracellular matrix in normal physiological
processes and tissue remodelling, as well as in disease proc-
esses, such as tumour metastasis. It is therefore plausible that
variants in matrix metalloproteinase genes may lead to variable
responses of the extracellular matrix to tumour invasion –
either increasing or decreasing the likelihood of tumour metas-
tasis. More detailed exploration is required to determine
whether rs1943779 alters expression of MMP7, how this
affects tumour invasiveness and whether other closely linked
variants are involved.
The protein encoded by MAP3K1 (MEK kinase) is a serine/
threonine kinase that occupies a pivotal role in a network of
phosphorylating enzymes integrating cellular responses to a
number of mitogenic and metabolic stimuli. We found that het-
erozygote carriers of the SNP rs889312 in MAP3K1 were
more likely to remain free of distant metastases compared with
common allele homozygotes, in contrast to a previous study in
which heterozygote and minor allele homozygote carriers of
this SNP were more likely to have lymph node positive breast
cancer at diagnosis [29]. TOX3 is an HMG box protein that is
involved in chromatin structural modification, and it is one of
the low penetrance breast cancer risk genes recently identi-
fied in genome-wide association studies [3]. It has also been
implicated in breast cancer metastasis to bone [30]. We found
that the risk for early relapse with distant metastases was
increased in heterozygotes and rare allele homozygotes of
SNP rs1420542.
Conclusion
In this cohort of women with early onset breast cancer, we
identified several SNPs in six genes that are associated with
the prognostic tumour characteristics of ER status and tumour
grade. If the type of breast cancer is determined by back-
ground genotype, then this finding has considerable implica-
tions for prevention options and also suggests that future
association studies should pay careful attention to breast can-
cer phenotype, because the same risk factors may not be rel-
evant to all types. Furthermore, we have identified three genes
associated with the duration of DDFS that are independent of
known clinical prognostic factors. Although all of the SNPs
tested were from candidate genes and many of these results
correspond with previous findings, the results must be treated
with caution because only three SNPs associated with ER sta-
tus remain significant after conservative correction for the
number of independent tests performed. Currently, the follow-
up time in the POSH cohort is short (median disease-free sur-
vival time for disease-free patients is 2.6 years [Table 1]), and
so it can only provide an early indication of SNPs that are asso-
ciated with rapidly progressive disease. Further genotyping in
the POSH cohort after longer periods of follow up and among
other similar cohorts will determine whether these SNPs
remain significant and whether these or different SNPs are
associated with more indolent disease progression. Our find-
ings, therefore, need replication in further breast cancer
cohorts in which tumour phenotypes and long-term follow-up
data are available. If genotyping for low penetrance risk vari-
ants is ever to be implemented as a cost-effective public health
strategy, it will be important to understand the implications of
genetic variants on tumour biology and treatment options as
well as for risk across the entire population.
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